XM does not provide services to residents of the United States of America.

US seeks new suppliers of highly used cancer drug methotrexate in short supply



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>EXCLUSIVE-US seeks new suppliers of highly used cancer drug methotrexate in short supply</title></head><body>

By Julie Steenhuysen and Michael Erman

June 9 (Reuters) -The U.S. Food and Drug Administration said on Friday it is seeking new suppliers to ease shortages of methotrexate, one of the most commonly used cancer drugs, building on its push to shore up two other scarce chemotherapy medicines.

An FDA spokesperson told Reuters the agency is looking for temporary importation options for the drug, which has been in shortage since March.

Methotrexate is an injected drug used to treat a wide variety of cancers ranging from acute lymphoblastic leukemia in children, breast cancer, lung cancer, bone cancers and certain types of head and neck cancers, according to the National Cancer Institute.

Last week, the FDA said it was looking for additional temporary suppliers for two other cancer chemotherapies, cisplatin and carboplatin. It has already signed off on allowing cisplatin made by China's Qilu Pharmaceutical to be sold in the country.

The FDA had not previously disclosed it is also looking for new methotrexate sources.

Some cancer drugs have been hard-hit by ongoing shortages in the United States, prompting doctors to ration drugs and complicating treatment plans for patients.

According to information released by U.S. Senators Gary Peters and Debbie Stabenow, shortages have been exacerbated by a disruption in supply from India-based manufacturer Intas Pharmaceuticals INTA.NS, which provides the U.S. market through its Accord Healthcare unit.

There are more than 130 drug formulations currently in shortage in the U.S., according to a list maintained by the FDA.

When faced with shortages, the FDA can make exceptions to allow products to be sold here outside of its usual oversight. A recent high-profile example was its opening of the baby formula market to additional manufacturers.

The regulator generally requires extra testing and oversight of new suppliers before signing off on them.

"The FDA may inspect the facility and conduct FDA sampling and testing as an additional level of oversight. The agency is doing both in this case," the regulator said in a statement when asked about the Qilu exemption.

Methotrexate works by slowing or stopping the growth of cancer cells and suppressing the immune system.

According to the American Society of Health-System Pharmacists, suppliers with methotrexate injections in shortage or on back order include Accord Healthcare, Fresenius Kabi, Pfizer PFE.N, Teva TEVA.TA and Hikma Pharmaceuticals HIK.L.

Methotrexate is also commonly used to treat autoimmune diseases such as rheumatoid arthritis.



Reporting by Julie Steenhuysen in Chicago and Michael Erman in New Jersey; Editing by Bill Berkrot

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.